罗格列酮对糖尿病大鼠血清MMP-9及外周血单核细胞MMP-9mRNA表达的影响

Effect of Rosiglitazone on Serum MMP-9 Concentration and Expression of Peripheral Monocyte MMP-9 mRNA in Rats with Diabetes

目的:观察过氧化物酶体增殖物激活受体γ(PPARγ)配体罗格列酮对糖尿病大鼠血清基质金属蛋白酶9(MMP-9)浓度和外周血单核细胞mRNA表达的影响。方法:30只SD大鼠随机分为三组,对照组、糖尿病组和罗格列酮组,每组10只。糖尿病组和罗格列酮组腹腔注射链脲霉素制作糖尿病大鼠模型后,罗格列嗣组以罗格列酮灌胃,5 mg·kg^(-1)·d^(-1),共28 d,对照组和糖尿病组以等量0.9%氯化钠溶液灌胃,比较治疗前、后的血清MMP-9浓度的变化,分离外周血单核细胞,RT-PCR检测MMP-9 mRNA的变化。结果:处理28 d后血清MMP.9浓度明显降低(P<0.01),外周血单核细胞MMP-9mRNA表达量明显降低。结论:罗格列酮可以降低糖尿病大鼠血清MMP-9及外周血单核细胞MMP-9mRNA表达,提示其可能通过抑制MMP-9表达稳定动脉粥样硬化斑块。

Objective： To observe the effect of rosiglitazone on serum MMP-9 concentration and expression of peripheral monocyte MMP-9 in rats with diabetes. Method： Thirty SD rats were randomly divided into 3 groups： control group （n = 10）, diabetes group （n = 10） and rosiglitazone group （n = 10）. The rat diabetic model was made by the intraperitoneal injection of streptozocin. After the model was made successfully, the rats of rosiglitazone group were treated with rosiglitazone （5 mg·kg^-1 ·d^-1 for 28d） by gavage and the rats of control group and diabetes group were treated with normal saline. The concentration of serum MMP -9 were detected by Enzyme-linked Immunosorbent Assay （ELISA） . The expression of peripheral monocyte MMP-9 mRNA were measured by RT-PCR. Result： The concentration of serum MMP-9 were lowered by rosiglitazone treatment. The expression of peripheral monocyte MMP-9 mRNA were inhibited by rosiglitazone treatment too. Conclusion： Rosiglitazone may be stable artery atherosclerosis plaque through inhibit the mRNA expression of MMP-9.